IgG-Binding Peptide for Site-Specific Antibody Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying antibodies are often non-specific, leading to reduced activity and increased costs due to the need for engineering antibodies and high development costs, with existing site-specific modification techniques facing challenges in maintaining antibody function and specificity.
Innovation Solution
Development of an IgG-binding peptide that allows for specific and convenient modification of IgG antibodies without reducing their activity, using a peptide with a specific amino acid sequence that can be modified with cross-linking agents to attach various compounds, enabling site-specific binding and conjugation with IgG.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional non-specific modification methods are used, then modification can be performed easily, but antibody activity is reduced and detection sensitivity decreases
Solution Approach 1:
The invention introduces an IgG-binding peptide as an intermediary component that specifically binds to the Fc region of IgG antibodies. This peptide serves as a mediator between the antibody and the compound to be introduced, enabling site-specific modification without directly modifying the antibody's antigen-binding sites. The peptide acts as a bridge that facilitates controlled conjugation while preserving antibody function.
Solution Approach 2:
The invention segments the modification process into two distinct steps: first, the IgG-binding peptide specifically binds to the Fc region of the antibody; second, the compound to be introduced is conjugated to the peptide. This segmentation allows for precise control of the modification site and number of ligands, preventing modification of the antigen-binding sites and maintaining antibody activity.
2Measurement precision
If the number of ligands is increased to improve detection sensitivity, then detection sensitivity improves, but physical property and structure of the antibody vary causing non-specific binding
Solution Approach 1:
The IgG-binding peptide serves as a controlled intermediary that regulates the number and positioning of ligands attached to the antibody. By controlling the stoichiometry of peptide-to-antibody conjugation and the number of ligands per peptide, the invention achieves optimal detection sensitivity while preventing excessive ligand attachment that would cause non-specific binding and structural changes.
Solution Approach 2:
The invention enables precise control of modification parameters including the number of ligands per antibody, the position of ligand attachment (specifically at the Fc region via the peptide), and the density of modification. These parameter controls allow optimization of detection sensitivity while maintaining antibody specificity and preventing non-specific binding.
3Reliability
If site-specific modification techniques are used, then antibody activity is maintained, but engineering of antibodies is required increasing development cost
Solution Approach 1:
The IgG-binding peptide acts as a versatile intermediary that can be conjugated to various compounds (detecting agents, drugs, etc.) without requiring engineering of the antibody itself. This approach maintains antibody activity while avoiding the high development costs associated with genetic engineering, as the peptide can be chemically conjugated to different functional molecules.
Solution Approach 2:
The IgG-binding peptide serves as a universal platform that can be used with multiple different compounds including detecting agents, drugs, and other functional molecules. This multi-functionality eliminates the need for separate engineering processes for each application, reducing development costs while maintaining site-specific modification capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IgG-binding peptide enables efficient and specific modification of IgG antibodies, maintaining their activity and allowing for the attachment of various compounds without side reactions, thus enhancing detection sensitivity and therapeutic effects.
Implementation Method 1
an IgG-binding peptide which binds to an Fc domain of IgG
Implementation Method 2
conjugate of the IgG-binding peptide modified with the cross-linking agent and IgG
Data Source
AI summary
It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.